

## X. REFERENCES

- Ahmad K.** 2000. More deaths from Rift Valley Fever in Saudi Arabia and Yemen. *Lancet*. Vol 356 Issue 9239, p. 1422.
- Al-Hazmi**, Ayoola AH, et.al. 2003. Epidemic Rift Valley Fever in Saudi Arabia: A clinical study of severe illness in humans. *Clin Infec Dis* 36:245-52.
- Ambrosio AM**, Riera LM, Saavedra Mdel C, Sabattini MS. 2006. Immune response to vaccination against Argentine hemorrhagic Fever in an area where different arenaviruses coexist. *Viral Immunol*. 19:196-201.
- American Public Health Association (APHA)**. 2004. "Arenaviral Hemorrhagic Fevers in the Western Hemisphere." Control of Communicable Diseases Manual, 18<sup>th</sup> Edition. Ed. David L. Heymann, MD. Washington, DC. pp 26-28.
- American Public Health Association (APHA)**. 2004 . Control of Communicable Diseases Manual, 18<sup>th</sup> Edition, David Heymann, MD, (pp. 180-182). August 27, 1977.
- Anderson**, G. W., T. W. Jr, Slone, C. J. Peters. 1987. Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats. *Microb Pathog*. 2(4):283-293.
- Arita I**, Jezek Z, Khodakevich L, Ruti K. (1985) Human monkeypox: a newly emerged orthopoxvirus zoonosis in the tropical rain forests of Africa. *Am J Trop Med Hyg*. Jul;34(4):781-9.
- Armstrong LR**, Dembry LM, Rainey PM, et.al., 1999. Management of a Sabia virus Infected patient in a US Hospital. *Infec Control Hosp Epid*. Vol 20 No. 3 pp 176- 182.
- Balkhy HH**, Memish ZA. 2003. Rift Valley fever: An uninvited zoonosis in the Arabian peninsula. *Int J Antimicrobial Agents*. 21:153-157.
- Barry M**, Russi M, Amrstrong L, Geller D, Tesh R, Dembry L, Gonzalez JP, Khan AS, Peters CJ. 1995. Brief Report: Treatment of a laboratory-acquired Sabia virus infection. *NEJM*. 333:294-296.
- Becker AL**. Scientists worry that Rift Valley fever could reach US. CIDRAP News, Jul 21, 2004
- Bian L** and D Liebner. 2007. A Network Model for Dispersion of Communicable Diseases. *Transactions in GIS*. 11(2): 155–173
- Bian, L.**, 2004. A conceptual framework for an individual-based spatially explicit epidemiological model, Environment and Planning B, 31(3): 381-395.

**Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, Meyerhoff A, O'Toole T, Ascher MS, Bartlett J, Breman JG, Eitzen EM, Hamburg M, Hauer J, Henderson DA, Johnson RT, Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM, Russell P, Tonat K. 2002. Hemorrhagic Fever Viruses as Biological Weapons. *JAMA* 287(18).**

**Bossi P, Tegnell A, Baka A, Van Loock F, Hendriks J, Werner A, Maidhof H, Gouvras G. 2004. Bichat guidelines for the clinical management of haemorrhagic fever viruses and bioterrorism-related haemorrhagic fever viruses. *Euro Surveill*; 9(12)[Epublsh]**

**Bouloy MC, Janzen, P. Vialat, H. Khun, J. Pavlovic, M. Huerre, and O. Haller. 2001. Genetic evidence for an interferon-antagonistic function of Rift Valley fever virus. *J Virol* 2001 Feb;75(3):1371-7.**

**Bressler DS and RJ Hawley. 2006. "Safety Considerations in the Biosafety Level 4 Maximum Containment Laboratory". In Biological Safety Principles and Practices, Fourth Edition. Eds. D.O. Fleming and D.L. Hunt. ASM Press, Washington, DC.**

**Briggiler AM, Enria DA, Feuillade MR, Maiztegui JI. 1987. Contagio interhumano e infeccion clinical con virus Junin en matrimonios residentes en el area endemica de fiebre hemorragica Argentina. *Medicina (B Aires)*. 47:565.**

**Centers for Disease Control and Prevention. *Arenavirus Fact Sheet*. Retrieved March 21, 2007, from The Center for Disease Control website : <http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/arena.htm>**

**Centers for Disease Control and Prevention. *Ebola Hemorrhagic Fever Fact Sheet*. Retrieved March 21, 2007, from The Center for Disease Control website : ([http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/Fact\\_Sheets/Ebola\\_Fact\\_Booklet.pdf](http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/Fact_Sheets/Ebola_Fact_Booklet.pdf))**

**Centers for Disease Control. (CDC) 1987. Recommendations for prevention of HIV transmission in health-care settings. *MMWR*; 36 (suppl 2S).**

**Centers for Disease Control. Update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. *MMWR* 1988; 37:377-382,387-88**

**Centers for Disease Control and Prevention. *Arenavirus Infection – Connecticut*, 1994. *MMWR*. 43:34.**

**Centers for Disease Control and Prevention and World Health Organization. *Infection Control for Viral Haemorrhagic Fevers in the African Health Care Setting*. 1998. Atlanta, 1998: 1-198.**

**Centers for Disease Control and Prevention/World Health Organization (CDC/WHO).** 1998. *Infection Control for Viral Haemorrhagic Fevers in the African Health Care Setting*. Retrieved August 1, 2007 from World Health Organization Website: [http://www.who.int/csr/resources/publications/ebola/WHO\\_EMCSR\\_98\\_2\\_EN/en/](http://www.who.int/csr/resources/publications/ebola/WHO_EMCSR_98_2_EN/en/).

**Centers for Disease Control and Prevention.** 2001. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBT, HCV, and HIV and Recommendations for Postexposure Prophylaxis. Retrieved August 6, 2007 from The Centers for Disease Control Website: <http://www.cdc.gov/mmwr/PDF/RR/RR5011.pdf>

**Centers for Disease Control and Prevention.** Vaccinia (Smallpox) Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR June 22, 2001 / 50(RR10); 1-25

**Centers for Disease Control and Prevention.** Rift Valley fever outbreak—Kenya, November 2006-January 2007. MMWR Feb. 2, 2007 / 49:1065-6.

**Centers for Disease Control and Prevention.** 2002. *Ebola Hemorrhagic Fever Information Packet*. Retrieved August 6, 2007 from The Centers For Disease Control Website: [http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/Fact\\_Sheets/Ebola\\_Fact\\_Booklet.pdf](http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/Fact_Sheets/Ebola_Fact_Booklet.pdf)

**Centers for Disease Control and Prevention.** Updated Interim Guidance for Use of Smallpox Vaccine, Cidofovir and Vaccinia Immunoglobulin (VIG) for Prevention and Treatment in the Setting of an Outbreak of Monkeypox Infections, posted July 18, 2003, 11:30 AM ET. [www.cdc.gov/ncid/od/monkeypox](http://www.cdc.gov/ncid/od/monkeypox)

**Centers for Disease Control and Prevention.** Multistate Outbreak of Monkeypox --- Illinois, Indiana, and Wisconsin, 2003. MMWR. June 13, 2003 / 52(23):537-540 <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5223a1.htm>

**Centers for Disease Control and Prevention.** Update: Multistate Outbreak of Monkeypox --- Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR June 20, 2003 / 52(24):561-564 <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5224a1.htm>

**Centers for Disease Control and Prevention.** Update: Multistate Outbreak of Monkeypox --- Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR June 27, 2003 / 52(25):589-590 <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5225a4.htm>

**Centers for Disease Control and Prevention.** Update: Multistate Outbreak of Monkeypox --- Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR July 4, 2003 / 52(26):616-618 <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5226a5.htm>

**Centers for Disease Control and Prevention.** Update: Multistate Outbreak of Monkeypox --- Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. *MMWR* July 11, 2003 / 52(27):642-646

<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5227a5.htm>

**Centers for Disease Control and Prevention.** 2003. *Questions and Answers about Monkeypox, November 2003.* Retrieved August 1, 2007, from The Center for Disease Control Website: <http://www.cdc.gov/ncidod/monkeypox/qa.htm>.

**Centers for Disease Control and Prevention.** 2004. *Updated Interim Case Definition for Human Monkeypox, January 2004.* Retrieved August 1, 2007, from The Center for Disease Control Website: <http://www.cdc.gov/ncidod/monkeypox/casedefinition.htm>.

**Centers for Disease Control and Prevention.** 2005. *Questions and Answers about Ebola Hemorrhagic Fever.* Retrieved August 1, 2007, from The Center for Disease Control Website: <http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/ebola/qa.htm>.

**Centers for Disease Control and Prevention.** 2005. Interim Guidance for Managing Patients with Suspected Viral Hemorrhagic Fever in U.S. Hospitals. [http://www.cdc.gov/ncidod/dhqp/bp\\_vhf\\_interimGuidance.html](http://www.cdc.gov/ncidod/dhqp/bp_vhf_interimGuidance.html)

**Centers for Disease Control and Prevention.** *Viral Hemorrhagic Fevers Fact Sheet.* Retrieved March 21, 2007, from The Center for Disease Control Website : <http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/vhf.htm>

**Charrel, RN and de Lamballerie, X.** 2003. Arenaviruses other than Lassa virus. *Antiviral Res.* Jan; 57(1-2):89-100.

**Charrel C, Feldmann R, Günther H, Vieth S, Drosten S. S.** 2005. Establishment of conventional and fluorescence resonance energy transfer-based real-time PCR assays for detection of pathogenic New World arenaviruses. *J Clin Virol.* 32(3):229-235.

**Chevalier, V., S. de la Rocque, T. Balder, L. Vial, and F. Roger.** 2004. Epidemiological processes involved in the emergence of vector-borne diseases: West Nile fever, Rift Valley fever, Japanese encephalitis and Crimean-Congo hemorrhagic fever. *Revue Scientifique et Technique.* 23:535-555.

**Coimbra TLM, Burattini MN, de Souza LTM, Ferreira IB, Rocco IM, da Rosa APAT, Vasconcelos PFC, Pinheiro FP, LeDuc JW, Rico-Hesse R, Gonzalez J, Jahrling PB, Rest RB.** (1994) New Arenavirus isolated in Brazil. *The Lancet.* Feb; 343:391-391

**Colin R Howard.** Viral Haemorrhagic Fevers. 2005. In *Perspectives in Medical Virology.* Vol . 11.

- Covert NM.** 1993. *Cutting Edge*. p. 23. Headquarters U.S. Army Garrison, Ft. Detrick, Maryland.
- Damon IK.** 2007. Poxviruses. In *Fields Virology*, Fifth Edition, Vol II. Eds. D.M. Knipe and P.M. Howley. Lippencott Williams & Wilkins, Philadelphia, PA. p. 2947.
- Daubney, R, R. Hudson, and P. C. Garnham.** 1931. Enzootic hepatitis or Rift Valley fever, an undescribed virus disease of sheep, cattle and man from East Africa. *The Journal of Pathology and Bacteriology* 34:545-579.
- Davies, FG, Linthicum KJ and AD James.** 1985. Rainfall and epizootic Rift Valley fever. *Bulletin of the World Health Organization*. 63:941-943.
- Digoutte J, and CJ Peters.** 1989. General aspects of the 1987 Rift Valley fever epidemic in Mauritania. *Research in Virology*. 140:27-30.
- Douglas RG, Wiebenga NH, Couch RB.** 1965. Bolivian hemorrhagic fever probably transmitted by personal contact. *Am J Epidemiol*. 82:85-91.
- Dyal J and Ben Fohner.** 2005. *Sabia virus*. Retrieved March 21, 2007, from Stanford University website: <http://www.stanford.edu/group/virus/arena/2005/SabiaVirus.htm>
- Emond RT, Evans B and ET Bowen.** 1977. "A Case of Ebola Virus Infection". *Brit Med J*. August 27 2(6086):541-544.
- Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID.** 1988. Smallpox and its eradication. History of international public health. No. 6. Geneva: World Health Organization.
- Fleischauer AT, Kile JC, Davidson M, et.al.,** 2005. Evaluation of Human-to-Human Transmission of Monkeypox from Infected Patients to Health Care Workers. *Clin Infect Dis* ; 40:689–94.
- Flick R and M. Bouloy,** 2005. Rift Valley Fever Virus. *Current Molecular Medicine*. 5: 827-834.
- Fogg CN, Americo JL, Lustig S, Huggins JW, Smith SK, Damon I, Resch W, Earl PL, Klinman DM, Moss B.** 2007. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. *Vaccine* Jan 3 [Epub ahead of print]
- Gargan TP II, Clark GG, Dohm DJ, Turell MJ and Charles L. Bailey.** 1988, Vector Potential of Selected North American Mosquito Species for Rift Valley Fever Virus *Am. J. Trop. Med. Hyg.*, 38(2), pp. 440-446

- Geisbert** T W and P. B. Jahrling. 2004. Exotic emerging viral diseases: progress and challenges. *Nat Med.* 10(12 Suppl):S110–21.
- Gerald** LM, E B John, and D Raphael. 2000. Principles & Practices of Infectious Diseases. Volume 2. Sixth edition. Page 2086.
- Gerberding** JL and DK Henderson. 1992. Management of Occupational Exposures to Bloodborne Pathogens: Hepatitis B virus, Hepatitis C virus and Human Immunodeficiency virus.. *Clin Infect Dis.*, 14: 1179-85.
- Harding** L and K Byer. 2006. The Epidemiology of Laboratory- associated Infections. In Biological Safety Principles and Practices, Fourth Edition. Eds. D.O. Fleming and D.L. Hunt. ASM Press, Washington, DC.
- Henderson** DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, Hauer J, Layton M, McDade J, Osterholm MT, O’Toole T, Parker G, Perl T, Russell PK, Tonat K. 1999. Smallpox as a biological weapon. *JAMA.* 281:2127-2137.
- Heraud** JM, Edghill-Smith Y, Ayala V, Kalisz I, Parrino J, Kalyanaraman VS, Manischewitz J, King LR, Hryniewicz A, Trindade CJ, Hassett M, Tsai WP, Venzon D, Nalca A, Vaccari M, Silvera P, Bray M, Graham BS, Golding H, Hooper JW, Franchini G. 2006. Subunit recombinant vaccine protects against monkeypox. *J. Immunol.* 177:2552-2564.
- Heymann** DL, Sczeniowski, M., and Esteves, K. 1998. Re-emergence of monkeypox in Africa: a review of the past six years. *Br. Med. Bull.* 54(3): 693-702
- Hoogstraal** H, Meegan JM, Khalil GM. 1979. The Rift Valley fever epizootic in Egypt, 1977-78. Ecological and entomological studies. *Tran. Royal Soc Trop Med Hyg.* 73:624-629.
- Huhn** GD, Bauer AM, Yorita K, Graham MB, Sejvar J, Likos A, et al. 2005. Clinical characteristics of human monkeypox and risk factors for severe disease. *Clin Infect Dis.* 41:1742–1751.
- Hutin** YJ, Williams RJ, Malfait P, et al. 2001. Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. *Emerg Inf Dis.* 7:434-438.
- Ibrahim** MS, M. J. Turell, F. K. Knauert, R. S. Lofts. 1997. Detection of Rift Valley fever virus in mosquitoes by RT-PCR. *Mol Cell Probes.* 11:11(1):49-53
- ITAR-TASS News Agency**, Fri 21 May 2004. research scientist dies of Ebola fever in lab accident. (in Russian and edited) reported on [http://www.promedmail.org/pls/askus/f?p=2400:1001:13521079354523145624::NO::F2400\\_P1001\\_BACK\\_PAGE,F2400\\_P1001\\_PUB\\_MAIL\\_ID:1010,25465](http://www.promedmail.org/pls/askus/f?p=2400:1001:13521079354523145624::NO::F2400_P1001_BACK_PAGE,F2400_P1001_PUB_MAIL_ID:1010,25465)

**Jaax** NK, Davis KJ, Geisbert TJ, Vogel P, Jaax GP, Topper M, and PB Jahrling. 1999. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidemies a Kikwit. *J Infect Dis.* Feb;179 Suppl 1:S36-47

**Jahrling** PB, Geisbert TW, Jaax NK, et al. Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 US epizootic. *Arch Virol* Suppl 1996;11:115-34.

**Jezeq** Z, Marennikova SS, Mutumbo M, Nakano JH, Paluku KM, Szczeniowski M. Human monkeypox: a study of 2,510 contacts of 214 patients. *J Infect Dis.* 1986 Oct;154(4):551-5.

**Jezeq** Z, B Grab and H Dixon. 1987. Stochastic Model for interhuman Spread of Monkeypox. *Am. J. Epidemiol.*; 126: 1082-1092

**Jezeq Z.** 1988. *Human Monkeypox.* Ed. Fenner, F. S. Karger Publishers, New York, NY.

**Khodakevich** L, Szczeniowski, M., Manbu-ma-Disu, Jezeq Z., Marennikova, S., Nakano, J., and Messinger, D. 1987. The role of squirrels in sustaining monkeypox virus transmission. *Trop. Geogr. Med.* 39:115-122.

**Kilgore** PE, Ksiazek TG, Rollin PE, Mills JN, Villagra MR, Montenegro MJ, Costales MA, Paredes LC, Peters CJ. 1997. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. *J Infect Dis.* 24:718-722.

**Ksiazek** TG, Jouan A, Meegan JM, LeGuenno B, Wilson ML, Peters CJ, Digoutte JP, Guillaud M, Merzoug NO, Touray EM. 1989. Rift Valley fever among domestic animals in the recent West African outbreak. *Res Virol.* 140: 67-77.

**Lacy** MD and RA Smego. 1996. Viral hemorrhagic fevers. *Adv Pediatr Infect Dis.* 12:21-53.

**Le May**, N, S. Dubaele, L. P. De Santis, A. Billecocq, M. Bouloy, J. M. Egly. 2004. TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. *Cell.* 116(4):541-550.

**Learned** LA, Renolds MG, et.al., 2005 Extended Interhuman transmission of Monkeypox in a Hospital Community in the Republic of the Congo, 2003 *Am J Trop Med Hyg*, August 1, 2005; 73(2): 428 - 434.

**Leroy** EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, Delicat A, Paweska JT, Gonzalez JP, Swanepoel R. Fruit bats as reservoirs of Ebola virus. *Nature.* 2005 Dec 1;438(7068):575-6

**Levine** RS, Peterson, A.T., Yorita, K.L., Carroll, D., Damon, I.K., and Reynolds, M.G. 2007. Ecological niche and geographical distribution of human monkeypox in Africa. *PLoS ONE* 2(1):e176.

**Likos** AM, Sammons SA, Olson VA, Frace AM, Li Y, Olsen-Rasmussen M, Davidson W, Galloway R, Khristova ML, Reynolds MG, Zhao H, Carroll DS, Curns A, Formenty P, Esposito JJ, Regnery RL, Damon IK. 2005. A tale of two clades: monkeypox viruses. *J Gen Virol.* 86:2661-2672.

**Linthicum**, KJ, A. Anyamba, C. J. Tucker, P. W. Kelley, M. F. Myers and C. J. Peters 1999. Climate and satellite indicators to forecast Rift Valley fever epidemics in Kenya. *Science* 285:397-400.

**Madani** TA, Al-Mazrou YY, et.al, 2003. Rift Valley Fever Epidemic in Saudi Arabia: Epidemiological, clinical and laboratory characteristics. *Clin Infec Dis* 37:1084-1092.

**Mahanty** S, Bray M. 2004. Pathogenesis of filoviral haemorrhagic fevers. *Lancet Infect Dis.* 4:487-498.

**Maiztegui** JI, McKee KT, Barrera Oro JG, Harrison LH, Gibbs PH, Feuillade MR, Enria DA, Briggiler AM, Levis SC, Ambrosio AM, Halsey NA, Peters CJ. 1998. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. *J Infect Dis.* 177:277–283.

**Martini** GA, Schmidt HA. 1968. Spermatogenic transmission of the "Marburg virus". (Causes of "Marburg simian disease"). *Klin Wochenschr* 46:398-400.

**Martini** GA. 1969. Marburg agent disease in man. *Trans R Soc Trop Med Hyg.* 63:295-302.

**Mathews** REF. 1982. Classification and nomenclature of viruses. *Intervirol.* 17:1 – 99.

**McIntosh** BM. 1972. Rift Valley fever. 1. Vector studies in the field. *Journal of the South Africa Veterinary Association.* 43:391-395.

**McIntosh** K, Cherry JD, Benenson AS, et al. Standard percutaneous {smallpox} revaccination of children who received primary percutaneous vaccination. *J Infect Dis* 1977;135:155-66.

**Meegan** JM. 1979. The Rift Valley fever epizootic in Egypt 1977-1978. 1. Description of the epizootic and virological studies. *Transactions of the Royal Society of Tropical Medicine Hygiene.* 73:618-623

**Membus**, CA. 1998. Rift Valley Fever. In Foreign Animal Diseases, *The Gray Book*. Retrieved August 2, 2007 from Foreign Animal Diseases, *The Gray Book*: [http://www.vet.uga.edu/vpp/gray\\_book02/fad/rvf.php](http://www.vet.uga.edu/vpp/gray_book02/fad/rvf.php)

**Mwanbal** PT, Tshioko KF, Moudi A, et al. 1997. Human monkeypox in Kasai Oriental, Zaire (1996-1997). *Euro Surveill.* 2:33-35.

**National Association of State Public Health Veterinarians.** 2006. Compendium of veterinary standard precautions: zoonotic disease prevention in veterinary personnel. Veterinary Infection Control Committee.  
<http://www.cfsph.iastate.edu/BRM/resources/stationary/CompendiumofVeterinaryStandardPrecautions.pdf>

**National Institutes of Health** and the Centers for Disease Control and Prevention. 2007. Biosafety in Microbiological and Biomedical Laboratories, Fifth Edition. Eds. DE Wilson and LC Chosewood. U.S. Government Printing Office, Washington, DC.

**Nierengarten** MB and Lutwick LI. 2002. Vaccines for Viral Hemorrhagic Fevers: Filoviruses and Arenaviruses *Medscape Infectious Diseases* 4(1), Retrieved August 1, 2007, from *Medscape*: <http://www.medscape.com/viewarticle/433535>

**Olaleye** OD, Tomori O, Schmitz H. 1996. Rift Valley fever in Nigeria: infections in domestic animals. *Rev Sci Tech Off Int Epizoot.* 15:937-946.

**Pan American Health Organization (PAHO).** 2003. “Brazilian Hemorrhagic Fever.” *Zoonoses and Communicable Diseases Common to Man and Animals, Third Edition. Volume II: Chlamydioses, Rickettsioses, and Viroses.* Eds. Pedro N. Acha and Boris Szyfres: Washington, DC. pp. 66-67.

**Pan American Health Organization (PAHO).** 2003. “Marburg Virus Disease.” *Zoonoses and Communicable Diseases Common to Man and Animals, Third Edition. Volume II: Chlamydioses, Rickettsioses, and Viroses.* Eds. Pedro N. Acha and Boris Szyfres.: Washington, DC. pp. 66-67.

**Paragas** J and TP Endy. 2006. Viral Agents of Human Disease: Biosafety Concerns. In *Biological Safety Principles and Practices*, Fourth Edition. Eds. D.O. Fleming and D.L. Hunt. ASM Press, Washington, DC.

**Parrino** J, and Graham, BS. 2006. Smallpox vaccines: Past, present and future. *J. Allergy Clin. Immunol.* 118(6):1320-1326.

**Peters, CJ.** 2002. Human Infection with Arenaviruses in the Americas. *Curr Top Microbiol Immunol.* 2002;262:65-74.

**Peters, CJ.** and J.M. Meegan. 1981. Rift Valley fever. In *CRC Handbook Series in Zoonoses.* Ed. J. H. Steele. Pp. 403-420. C.R.C. Press, Boca Raton, FL.

**Peters** CJ, D. Jones, R. Trottier, J. Donaldson, J. White, E. Stephen, and T.W.Jr. Slone. 1988. Experimental Rift Valley fever in Rhesus macaques. *Archiv. Virol.* 99:31-44

**Radoshitzky** SR, Abraham J, Spiropoulou CF, Kuhn JH, Nguyen D, Li W, Nagel J, Schmidt PJ, Nunberg JH, Andrews NC, Farzan M, Choe H. 2007. Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. *Nature*. 446(7131):92-96.

**Rodriguez** L, De Roo A, Guimard Y, Trappier SG, Sanchez A, Bressler D, Williams AJ, AK Rowe, Bertolli J, Khan AS, Ksiazek TG, Peters J, and Nichol ST. 1999. Persistence and Genetic Stability of Ebola Virus during the Outbreak in Kikwit, Democratic Republic of the Congo, 1995. *J Infect Dis*. Supplement 179:S170-S176

**Rojek** JM, Spiropoulou CF, Kunz S. 2006. Characterization of the cellular receptors for the South American hemorrhagic fever viruses Junin, Guanarito, and Machupo. *Virology*. 349:476-491.

**Rowe** AK, Bertolli J, Khan AS, Mukunu R, Muyembe-Tamfum JJ, Bressler D, Williams AJ, Peters CJ, Rodriguez L, Feldman H, Nichol ST, Rollin PE, Ksiazek TG. 1999. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. *J Infect Dis*. Supplement 179:S28-S35.

**Sabin** A B and R. W. Blumberg. 1947. Human infection with Rift valley fever virus. *Proc Soc Exp Biol Med* 64:384-389

**Sale** TA, Melski, J.W., and Stratman, EJ. 2006. Monkeypox: An epidemiological and clinical comparison of African and US disease. *J. Am. Acad. Dermatol*. 55:478-481.

**Sall**, AA, P.M. DE, A. Zanutto, O.K. Sene, H.G. Zeller, J.P. Digoutte, Y. Thiongane and M. Bouloy. 1999. Genetic reassortment of the Rift Valley Fever Virus in Nature. *J Virol*. Oct: 8196-8200.

**Sbrana** E, Jordan R, Hruby DE, Mateo RI, Xiao S-Y, Siirin M, Newman PC, Tavassos Da Rosa APA, Tesh RB. 2007. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. *Am J Trop Med Hyg*. 76:768-773.

**Schmaljohn** CS and Nichol ST. 2007. *Bunyaviridae*. In *Fields Virology*, Fifth Edition, Vol. II. Eds. D.M. Knipe and P.M. Howley. Lippencott Williams & Wilkins, Philadelphia, PA., p. 1770.

**Shimshony** A, and R. Barzilal. 1983. Rift Valley fever. *Adv. Vet. Sci. Comp. Med*. 27:347-425.

**Siam** AL, J. M. Meegan, K.F. Gharbawi. 1980. Rift Valley fever ocular manifestations: observations during the 1977 epidemic in Egypt. *Br. J Ophthalmaol*. 64(5):366-374.

**Sliva K**, and Schnierle, B. 2007. From actually toxic to highly specific – novel drugs against poxviruses. *Virology Journal* 4:8.

**Smith DH**, Isaacson M, Johnson KM, et al. 1982. Marburg virus disease in Kenya. *Lancet*. 1:816-820.

**Smith GL**, Mackett M, Moss B. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. *Nature* 1983;302:490-5.

**Spiropoulou CF**, Kunz S, Rollin PE, Campbell KP, Oldstone MB. 2002. New World arenavirus clade C, but not clade A and B viruses, utilizes alpha-dystroglycan as its major receptor. *J Virol*. 76:5140-6.

**Stittelaar KJ**, Neyts J, Naesens L, van Amerongen G, van Lavieren RF, Holý A, De Clercq E, Niesters HG, Fries E, Maas C, Mulder PG, van der Zeijst BA, Osterhaus AD. 2006. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. *Nature*. 439:745-748.

**University of Massachusetts**. 2004. *Benchmarks*.

**US Department of Health and Human Services**. 2007. *Biosafety in Microbiological and Biomedical Laboratories (BMBL)* 5<sup>th</sup> Edition. Centers for Disease Control and Prevention and National Institutes of Health. US Government Printing Office: Washington, DC. <http://www.cdc.gov/od/ohs/biosfty/bmb15/bmb15toc.htm>

**Vieth S**, Drosten C, Charrel R, Feldmann H, Günther S. Vieth S, Drosten. 2005. Establishment of conventional and fluorescence resonance energy transfer-based real-time PCR assays for detection of pathogenic New World arenaviruses. *J Clin Virol*. 32:229-235.

**von Magnus P**, Andersen, E.K., Petersen, K.B., and Birch-Andersen, A. 1959. A pox-like disease in cynomolgous monkeys. *Acta Path. Microbiol. Scand*. 46:56-176.

**Wilson M. L**. 1994. Rift Valley fever virus ecology and the epidemiology of disease emergence. *Ann N Y Acad Sci*. Dec 15:740:169-80.

**World Health Organization (WHO)**. 2004. Ebola Haemorrhagic fever Fact Sheet no. 103. Retrieved August 1, 2007, from The World Health Organization Website: <http://www.who.int/mediacentre/factsheets/fs103/en/>

**Yadani F**, A. Kohl, C. Prehaud, A. Billecocq, M. Bouloy. 1999. The carboxy-terminal acidic domain of Rift Valley fever virus NSs protein is essential for the formation of filamentous structures but not for the nuclear localization of the protein. *J. Virol*. 73(6):5018-5025

**Zaucha** GM, Jahrling PB, Geisbert, TW, Swearengen JR, and Hensley L. 2001. The pathology of experimental aerosolized monkeypox virus infection in cynomolgous monkeys (*Macaca fascicularis*). *Lab. Invest.* 81(12):1581-1600.